Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Merger or Acquisition (June 2024)
13 slides from Simulations Plus's merger presentation, Jun 12, 2024
Slide 1: Pro-ficiency Acquisition
1 Pro-ficiency Acquisition June 12, 2024
Slide 2: Safe Harbor Statement
©2024, Simulations Plus, Inc. All Rights Reserved. With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best es
Slide 3: Today's Speakers
©2024, Simulations Plus, Inc. All Rights Reserved. Today’s Speakers Shawn O’Connor Chief Executive Officer Will Frederick Chief Financial Officer and Chief Operating Officer Michael Raymer Chief Executive Officer, Pro-ficiency
Slide 4: Pro-ficiency Acquisition Overview
©2024, Simulations Plus, Inc. All Rights Reserved. Pro-ficiency Acquisition Overview • Transaction Terms – $100M purchase price – 100% cash consideration, funded from existing cash and investment resources • Expands Simulations Plus’ presence across the drug development continuum, providing clients
Slide 5: Pro-ficiency At a Glance
©2024, Simulations Plus, Inc. All Rights Reserved. Pro-ficiency At a Glance • Leading provider of simulation-enabled performance and intelligence solutions for clinical and commercial drug development • Suite of software and services, developed with AI technologies, is highly complementary and syner
Slide 6: Strategic Rationale
©2024, Simulations Plus, Inc. All Rights Reserved. Strategic Rationale • Expands Simulations Plus’ presence along the drug development value chain, leveraging its scientific skills, drug development expertise, data management acumen, predictive analytics and biosimulations capabilities • Broadens an
Slide 7: Complementary Businesses
©2024, Simulations Plus, Inc. All Rights Reserved. Complementary Businesses Simulations Plus Pro-ficiency Total Addressable Market (TAM) $4B $4B 2023 Revenue $60M (FY) $15M (CY) Top 20 Pharma 18 Top 20 Logos 8 Top 20 Logos Markets Served • Drug Discovery • Clinical Development • Regulatory • Clinica
Slide 8: Expanded Offerings Across the Pharma Value Chain
©2024, Simulations Plus, Inc. All Rights Reserved. Expanded Offerings Across the Pharma Value Chain
Slide 9: Key Takeaways
©2024, Simulations Plus, Inc. All Rights Reserved. Key Takeaways • Complementary capabilities with expertise and services that are grounded in science • Focus on applying advanced technologies, including AI, to enhance actionable data analytics • Continues Simulations Plus’ journey to assist its cli
Slide 10: Investor Relations Contacts
Investor Relations Contacts: Lisa Fortuna Financial Profiles 310-622-8251 slp@finprofiles.com Renee Bouche Simulations Plus Investor Relations 661-723-7723 renee.bouche@simulations-plus.com
Slide 11: Glossary
©2024, Simulations Plus, Inc. All Rights Reserved. Glossary 11 ADMET Predictor®: Flagship machine learning platform for absorption, distribution, metabolism, excretion and toxicity (ADMET) modeling AI-Driven Drug Design (AIDD): ADMET Predictor module DILIsym®: Quantitative systems toxicology (QST) s
Slide 12: Glossary
©2024, Simulations Plus, Inc. All Rights Reserved. RENAsym: QST software for predicting and understanding drug-induced kidney injury Thales : A model building platform that automates and streamlines the QSP modeling process Simulx : Clinical trial simulations NAFLDsym®: QSP software for modeling non
Slide 13: Glossary
©2024, Simulations Plus, Inc. All Rights Reserved. Simulation-based training to drive study quality and protocol adherence Simulation-enabled communications that engage and educate patients Glossary 13 Customizable KOL insights platform to facilitate strategic drug development decisions Protocol opt